

# CITATION REPORT

List of articles citing

Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study

DOI: 10.1161/01.cir.0000057810.48709.f6  
Circulation, 2003, 107, 1486-91.

**Source:** <https://exaly.com/paper-pdf/35696803/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
609	Serum MCP-1 and VEGF levels are not affected by inhibition of the renin-angiotensin system in patients with acute myocardial infarction. <b>2003</b> , 17, 249-55		18
608	C-reactive protein, inflammation, and coronary risk: an update. <b>2003</b> , 21, 327-31		11
607	Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. <i>Circulation</i> , <b>2003</b> , 108, 2317-22	16.7	742
606	The role of estrogen in cardiovascular disease. <b>2003</b> , 115, 325-44		120
605	Proinflammatory cytokines: predictors of a failing heart?. <i>Circulation</i> , <b>2003</b> , 107, 1460-2	16.7	54
604	The relationship between functional status and inflammatory disease in older adults. <b>2003</b> , 58, 995-8		14
603	Statins for heart failure: a potential for new treatment. <b>2003</b> , 60, 217-9		12
602	Protein C and thrombomodulin in human acute lung injury. <b>2003</b> , 285, L514-21		260
601	Is the Inflammatory Marker an Important Prognostic Predictor in Patients with Non-ischemic Heart Failure?. <b>2003</b> , 33, 353		
600	[Cytokines and heart failure]. <b>2004</b> , 39, 197-203		
599	Left ventricular mass increases with deteriorating glucose tolerance, especially in women: independence of increased arterial stiffness or decreased flow-mediated dilation: the Hoorn study. <b>2004</b> , 27, 522-9		44
598	Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. <b>2004</b> , 38, 943-50		104
597	Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women. <b>2004</b> , 27, 47-52		183
596	Inflammatory cytokines and postmyocardial infarction remodeling. <b>2004</b> , 94, 1543-53		800
595	Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting. <b>2004</b> , 25, 1029-35		30
594	Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. <b>2004</b> , 19, 1154-60		157
593	Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. <b>2004</b> , 19 Suppl 5, V67-72		54

592	Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. <b>2004</b> , 286, E201-7	106
591	Biomarkers of cardiac disease. <b>2004</b> , 4, 805-20	21
590	Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. <b>2004</b> , 43, 607-16	163
589	High-sensitivity C-reactive protein: Clinical importance. <b>2004</b> , 29, 439-493	14
588	Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. <b>2004</b> , 9, 21-31	41
587	Nitric oxide and promotion of cardiac myocyte apoptosis. <b>2004</b> , 263, 35-53	19
586	The effect of medical treatment on the level of C-Reactive protein and leukocyte count in patients with congestive heart failure. <b>2004</b> , 13, 168-172	
585	A novel data mining approach to the identification of effective drugs or combinations for targeted endpoints--application to chronic heart failure as a new form of evidence-based medicine. <b>2004</b> , 18, 483-9	29
584	New pharmacological strategies in chronic heart failure. <b>2004</b> , 18, 491-501	4
583	[Mechanisms of inflammation in heart failure]. <b>2004</b> , 29, 782-7	3
582	Risk factors for heart failure. <b>2004</b> , 88, 1145-72	83
581	Impact of obesity on the risk of heart failure and survival after the onset of heart failure. <b>2004</b> , 88, 1273-94	82
580	Epidemiología de la insuficiencia cardíaca. <b>2004</b> , 57, 163-170	60
579	Epidemiology of Heart Failure. <b>2004</b> , 57, 163-170	1
578	Anti-inflammatory therapy for heart failure. <b>2004</b> , 4, 171-6	19
577	Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. <b>2004</b> , 37, 889-96	38
576	Physiology, genetics, and cardiovascular disease: focus on African Americans. <b>2004</b> , 6, 11-8	17
575	High-sensitivity C-reactive protein: Clinical importance. <b>2004</b> , 29, 439-493	30

574	Novel markers for heart failure diagnosis and prognosis. <b>2005</b> , 20, 201-10	59
573	Prevalence and implications of diastolic dysfunction after subarachnoid hemorrhage. <b>2005</b> , 3, 132-8	49
572	Interleukin-6 modulates plasma cholesterol and C-reactive protein concentrations in nonagenarians. <b>2005</b> , 53, 1552-8	15
571	C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. <b>2005</b> , 68, 773-8	14
570	Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation. <b>2005</b> , 130, 113-20	12
569	High levels of C-reactive protein with low total cholesterol concentrations additively predict all-cause mortality in patients with coronary artery disease. <b>2005</b> , 35, 104-11	5
568	Predictive value of high-sensitivity C-reactive protein in patients with idiopathic dilated cardiomyopathy. <b>2005</b> , 28 Suppl 1, S233-6	6
567	Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. <b>2005</b> , 95, 88-90	37
566	Cardiovascular disease, risk factors and heart rate variability in the elderly general population: design and objectives of the CARdiovascular disease, Living and Ageing in Halle (CARLA) Study. <b>2005</b> , 5, 33	84
565	The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. <b>2005</b> , 52, 412-20	316
564	Dietary fiber, inflammation, and cardiovascular disease. <b>2005</b> , 49, 594-600	104
563	Diabetic cardiomyopathy in uncomplicated type 2 diabetes is associated with the metabolic syndrome and systemic inflammation. <b>2005</b> , 48, 1669-70	35
562	Extracorporeal ultrafiltration for acute exacerbations of chronic heart failure: report from the Acute Dialysis Quality Initiative. <b>2005</b> , 28, 466-76	19
561	Frailty. <b>2005</b> , 51-77	
560	Cardiovascular Disease in the Elderly. <b>2005</b> ,	
559	C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. <b>2005</b> , 7, 748-54	33
558	Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. <b>2005</b> , 91, 32-7	51
557	End stage ischaemic heart failure. <b>2005</b> , 91, 37	

556	Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. <b>2005</b> , 16 Suppl 1, S83-8		183
555	N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. <b>2005</b> , 293, 1609-16		386
554	C-reactive protein in end-stage renal disease: are there reasons to measure it?. <b>2005</b> , 23, 72-8		49
553	Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. <b>2005</b> , 172, 1199-209		154
552	Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. <i>Circulation</i> , <b>2005</b> , 111, 863-70	16.7	159
551	C-reactive protein in heart failure: prognostic value and the effect of valsartan. <i>Circulation</i> , <b>2005</b> , 112, 1428-34	16.7	329
550	Social relationships, sleep quality, and interleukin-6 in aging women. <b>2005</b> , 102, 18757-62		155
549	Monocyte chemoattractant protein 1: a possible link between visceral adipose tissue-associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity. <b>2005</b> , 153, 871-7		45
548	Statin use and survival outcomes in elderly patients with heart failure. <b>2005</b> , 165, 62-7		95
547	C-reactive protein predicts death in patients with non-ischemic cardiomyopathy. <b>2005</b> , 104, 196-201		10
546	Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. <b>2005</b> , 45, 69-74		38
545	[Inhaled corticosteroid therapy: a treatment with multiple impacts]. <b>2005</b> , 61 Spec No 1, 30-3		
544	Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. <b>2005</b> , 14, 2413-8		350
543	Frailty in the older adult. <b>2005</b> , 5, 39-41		
542	Adipose tissue, inflammation, and cardiovascular disease. <b>2005</b> , 96, 939-49		1539
541	Cardiac remodeling and failure: from molecules to man (Part I). <b>2005</b> , 14, 1-11		90
540	Global inflammation predicts cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. <b>2005</b> , 150, 900-6		51
539	Inflammation, as measured by the erythrocyte sedimentation rate, is an independent predictor for the development of heart failure. <b>2005</b> , 45, 1802-6		44

538	Novel metabolic risk factors for heart failure. <b>2005</b> , 46, 2054-60	82
537	Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. <b>2005</b> , 7, 195-207	52
536	Cardiovascular Biomarkers. <b>2006</b> ,	2
535	Cytokines and Disability in Older Adults. <b>2006</b> , 397-404	
534	The role of erythropoietin in myocardial protection: potential mechanisms and applications. <b>2006</b> , 4, 41-50	8
533	Metabolic syndrome and heart failure. <b>2006</b> , 2, 1-11	3
532	Acute renal failure: much more than a kidney disease. <b>2006</b> , 26, 105-13	105
531	[Diabetic miocardiopathy]. <b>2006</b> , 127, 584-94	7
530	Trans fatty acids and cardiovascular disease. <b>2006</b> , 354, 1601-13	1171
529	Biomarkers of Inflammation. <b>2006</b> , 295-318	
528	Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. <b>2006</b> , 47, 962-8	202
527	High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. <b>2006</b> , 12, 61-5	58
526	Socioeconomic factors as predictors of incident heart failure. <b>2006</b> , 12, 540-5	32
525	Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis. <b>2006</b> , 2, 320-9	37
524	Inflammatory markers and loss of muscle mass (sarcopenia) and strength. <b>2006</b> , 119, 526.e9-17	594
523	Prediction of mortality risk in the elderly. <b>2006</b> , 119, 519-25	112
522	Clinical significance of calcification of the fibrous skeleton of the heart and aortosclerosis in community dwelling elderly. The Cardiovascular Health Study (CHS). <b>2006</b> , 151, 39-47	110
521	Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. <b>2006</b> , 152, 94-101	74

520	C-reactive protein and risk of heart failure. The Rotterdam Study. <b>2006</b> , 152, 514-20	82
519	Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. <b>2006</b> , 20, 201-9	321
518	Noncanonical cAMP pathway and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in neonatal mouse cardiac fibroblasts. <b>2006</b> , 40, 384-93	90
517	. <b>2006</b> ,	1
516	Immune Modulatory Therapies in Heart Failure: Using Myocarditis to Gain Mechanistic Insights. 174-186	
515	Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. <b>2006</b> , 110, 483-9	76
514	Jak/STAT/SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart. <b>2006</b> , 26, 226-34	81
513	Contributions of cytokines to nonthyroidal illness. <b>2006</b> , 13, 444-450	3
512	Diabetes, gender, and left ventricular structure in African-Americans: the atherosclerosis risk in communities study. <b>2006</b> , 4, 43	10
511	Effect of moderate red wine intake on cardiac prognosis after recent acute myocardial infarction of subjects with Type 2 diabetes mellitus. <b>2006</b> , 23, 974-81	73
510	Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. <b>2006</b> , 4, 1017-22	65
509	Clinical effects of online dialysate and infusion fluids. <b>2006</b> , 10 Suppl 1, S60-6	4
508	BMI modifies associations of IL-6 genotypes with insulin resistance: the Framingham Study. <b>2006</b> , 14, 1454-61	28
507	Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: correlation with cardiovascular risk. <b>2006</b> , 70, 157-64	84
506	Kortademigheid: is het pulmonaal of cardiaal, of beide?. <b>2006</b> , 22, 114-120	
505	Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review. <b>2006</b> , 11, 333-4	22
504	Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. <b>2006</b> , 49, 1637-46	61
503	Screening for ventricular remodeling. <b>2006</b> , 3, 5-13	7

502	Inflammation markers predicting frailty and mortality in the elderly. <b>2006</b> , 80, 219-27	266
501	Diagnosis and management of stage a heart failure. <b>2006</b> , 12, 146-52	1
500	Inflammatory biomarkers in heart failure. <b>2006</b> , 12, 324-8	54
499	Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. <b>2006</b> , 97, 249-52	46
498	Relation of social integration to inflammatory marker concentrations in men and women 70 to 79 years. <b>2006</b> , 97, 1010-6	121
497	Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. <b>2006</b> , 54, 60-7	139
496	The predictive value of C-reactive protein in end-stage renal disease: is it clinically significant?. <b>2006</b> , 24, 335-41	18
495	Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study. <b>2006</b> , 27, 2346-52	30
494	Growth factor-mediated reversal of senescent dysfunction of ischemia-induced cardioprotection. <b>2006</b> , 290, H525-30	16
493	Metabolic syndrome and risk for heart failure in middle-aged men. <b>2006</b> , 92, 1409-13	88
492	The failing heart under stress: echocardiography is an essential monitoring tool in the intensive care unit. <b>2006</b> , 10, 111-5	3
491	Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. <b>2007</b> , 66, 76-80	55
490	C-Reactive Protein as a Tool for Risk Assessment in Primary Prevention. <b>2006</b> , 237-260	
489	Association of educational level with inflammatory markers in the Framingham Offspring Study. <b>2006</b> , 163, 622-8	74
488	The future of cardiovascular biomarkers. <b>2006</b> , 4, 228-31	6
487	Sleep disturbances independently predict heart failure in overweight middle-aged men. <b>2007</b> , 9, 184-90	22
486	Risk Factors for Development of Heart Failure. <b>2007</b> , 3, 1-9	1
485	Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. <b>2007</b> , 68, 1902-8	351



484	Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. <b>2007</b> , 53, 1800-7		63
483	Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. <b>2007</b> , 28, 1739-45		58
482	Chapter 1: Introduction. <b>2007</b> , 14, S2-S113		
481	Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. <i>Circulation</i> , <b>2007</b> , 115, 1528-36	16.7	262
480	The biological response to online hemodiafiltration. <b>2007</b> , 158, 194-200		1
479	Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure. <b>2007</b> , 46, 1337-43		28
478	Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. <b>2007</b> , 17, 294-302		71
477	An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. <b>2007</b> , 153, 74-81		345
476	Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. <b>2007</b> , 153, 1055.e1-8		56
475	C-reactive protein and heart failure after myocardial infarction in the community. <b>2007</b> , 120, 616-22		54
474	Relationship between heart failure and lipids: the paradigm continues to evolve. <b>2007</b> , 13, 254-8		9
473	Cytokine activation and disease progression in patients with stable moderate chronic heart failure. <b>2007</b> , 26, 622-9		17
472	Cytokines in HIV-associated cardiomyopathy. <b>2007</b> , 120, 150-7		53
471	Lipoprotein-associated phospholipase A(2) : review of its role as a marker and a potential participant in coronary endothelial dysfunction. <b>2007</b> , 11, 219-26		15
470	Risk Factor Management and Lifestyle Modification in Heart Failure. <b>2007</b> , 315-330		
469	Promising new causal explanations for obesity and obesity-related diseases. <b>2007</b> , 8, 223-33		16
468	Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. <b>2007</b> , 50, 1657-65		271
467	Role of Cytokines and Inflammation in Hypertension. <b>2007</b> , 229-239		

466	Effect of pravastatin on markers of endothelial activation in dialysis patients. <b>2007</b> , 12, 234-8	3
465	C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. <b>2007</b> , 262, 526-36	44
464	Factors influencing spontaneous mobilization of CD34+ and CD133+ progenitor cells after myocardial infarction. <b>2007</b> , 37, 842-51	25
463	Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. <b>2007</b> , 61, 611-21	28
462	Cardiovascular diseases and future risk of hip fracture in women. <b>2007</b> , 18, 1355-62	87
461	Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration?. <b>2007</b> , 46, 230-7	67
460	Acute phase proteins and systolic dysfunction in subjects with acute myocardial infarction. <b>2008</b> , 26, 196-202	20
459	Diastolic heart function in RA patients. <b>2008</b> , 28, 513-9	27
458	Role of lipoprotein-associated phospholipase A2 in atherosclerosis. <b>2008</b> , 10, 230-5	22
457	Beneficial effects of cardiac rehabilitation and exercise after percutaneous coronary intervention on hsCRP and inflammatory cytokines in CAD patients. <b>2008</b> , 455, 1081-8	33
456	Adeno-associated virus vector-mediated systemic interleukin-10 expression ameliorates hypertensive organ damage in Dahl salt-sensitive rats. <b>2008</b> , 10, 368-74	30
455	Biomarkers in heart failure. <b>2008</b> , 358, 2148-59	923
454	Management of chronic nonmalignant pain with nonsteroidal antiinflammatory drugs. Joint opinion statement of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy. <b>2008</b> , 28, 788-805	20
453	Suppression of tissue necrosis factor-alpha or hydrogen peroxide-activated primary human T lymphocytes by Ginkgo biloba extract through down-regulation of activator protein-1 signal transduction. <b>2008</b> , 15, 170-6	2
452	Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. <b>2008</b> , 51, 1775-83	263
451	The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. <b>2008</b> , 10, R70	30
450	Predictive value of high sensitivity CRP in patients with diastolic heart failure. <b>2008</b> , 125, 347-51	35
449	Inflammatory pathways in patients with heart failure and preserved ejection fraction. <b>2008</b> , 129, 111-7	41

448	Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. <b>2008</b> , 155, 75-81	155
447	Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. <b>2008</b> , 121, S15-20	72
446	Trans fatty acids: effects on cardiometabolic health and implications for policy. <b>2008</b> , 79, 147-52	101
445	Effect of oral anticoagulant therapy on thrombospondin-1 and von Willebrand factor in patients with stable heart failure. <b>2008</b> , 121, 611-5	7
444	Cytokines and myocardial dysfunction: state of the art. <b>2008</b> , 14, 61-74	74
443	Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. <b>2008</b> , 14, 467-74	69
442	Comparing Type D personality and older age as correlates of tumor necrosis factor-alpha dysregulation in chronic heart failure. <b>2008</b> , 22, 736-43	44
441	Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. <b>2008</b> , 14, 1209-16	69
440	Increased expression of interleukin-1beta and its novel splice variant in canine hearts with volume overload. <b>2008</b> , 44, 352-60	9
439	Age-related increases in circulating inflammatory markers in men are independent of BMI, blood pressure and blood lipid concentrations. <b>2008</b> , 196, 298-305	75
438	The cytokine basis of cachexia and its treatment: are they ready for prime time?. <b>2008</b> , 9, 219-36	38
437	CPAP decreases plasma levels of soluble tumour necrosis factor-alpha receptor 1 in obstructive sleep apnoea. <b>2008</b> , 32, 1009-15	91
436	Cardiac troponin-I and risk of heart failure: a community-based cohort study. <b>2009</b> , 30, 773-81	48
435	Metabolic syndrome, inflammation, and incident heart failure in the elderly: the cardiovascular health study. <b>2008</b> , 1, 242-8	59
434	Using peripheral blood mononuclear cells to determine proteome profiles in human cardiac failure. <b>2008</b> , 10, 749-57	5
433	C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. <b>2008</b> , 10, 63-9	50
432	Single nucleotide polymorphisms in inflammation-related genes and mortality in a community-based cohort in Washington County, Maryland. <b>2008</b> , 167, 807-13	27
431	Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. <b>2008</b> , 5, 310-8	34

430	Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. <i>Circulation</i> , <b>2008</b> , 117, 2544-65	16.7	394
429	Biomarkers for Risk Stratification in Patients with Heart Failure. 116-139		
428	The inflammatory status of old age can be nurtured from the intestinal environment. <b>2008</b> , 11, 13-20		152
427	. <b>2008</b> ,		1
426	Does absolute neutrophilia predict early congestive heart failure after acute myocardial infarction? A cross-sectional study. <b>2008</b> , 101, 19-23		14
425	New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. <b>2008</b> , 3, 341-9		25
424	Biomarkers in heart failure. <b>2009</b> , 14, 2484-93		8
423	Multimarker Approach in Cardiovascular Risk Prediction. <b>2009</b> , 26, 273-285		17
422	Lipoprotein components and risk of congestive heart failure in 84,740 men and women in the Apolipoprotein MOrtality RiSk study (AMORIS). <b>2009</b> , 11, 1036-42		18
421	Effects of music therapy on autonomic nervous system activity, incidence of heart failure events, and plasma cytokine and catecholamine levels in elderly patients with cerebrovascular disease and dementia. <b>2009</b> , 50, 95-110		106
420	Macrophage depletion in hypertensive rats accelerates development of cardiomyopathy. <b>2009</b> , 14, 68-75		47
419	Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. <b>2009</b> , 64, 1183-9		426
418	Carotid intima-media thickness, systemic inflammation, and incidence of heart failure hospitalizations. <b>2009</b> , 29, 1691-5		22
417	Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. <b>2009</b> , 2, 429-36		15
416	Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. <i>Circulation</i> , <b>2009</b> , 120, 2345-51	16.7	86
415	Leukocyte count and incidence of hospitalizations due to heart failure. <b>2009</b> , 2, 217-22		68
414	Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. <b>2009</b> , 55, 265-73		45
413	Biomarkers of risk stratification in congestive heart failure: North American view. <b>2009</b> , 3, 443-52		2

412	Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. <b>2009</b> , 11, 130-9	324
411	Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. <b>2009</b> , 29, 1144-9	62
410	Comparative value of simple inflammatory markers in the prediction of left ventricular systolic dysfunction in postacute coronary syndrome patients. <b>2009</b> , 2009, 826297	4
409	Body mass index and vigorous physical activity and the risk of heart failure among men. <i>Circulation</i> , <b>2009</b> , 119, 44-52	16.7 172
408	Association of multiple anthropometrics of overweight and obesity with incident heart failure: the Atherosclerosis Risk in Communities study. <b>2009</b> , 2, 18-24	82
407	Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort. <b>2009</b> , 55, 1539-45	44
406	Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. <b>2009</b> , 9, 1773-83	81
405	Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. <b>2009</b> , 103, 1269-74	50
404	Causes and consequences of inflammation on anemia management in hemodialysis patients. <b>2009</b> , 13, 222-34	22
403	Predictors of interleukin-6 elevation in older adults. <b>2009</b> , 57, 1672-7	20
402	Osteoporosis and congestive heart failure (CHF) in the elderly patient: double disease burden. <b>2009</b> , 49, 250-254	40
401	Circulating IL-8 levels in heart failure patients with and without metabolic syndrome. <b>2009</b> , 405, 139-42	9
400	Muscle wastage in heart failure: orphan of the heart failure. <b>2009</b> , 135, 233-6	5
399	Resistin, adiponectin, and risk of heart failure the Framingham offspring study. <b>2009</b> , 53, 754-62	205
398	Heart failure in Hispanics. <b>2009</b> , 53, 1167-75	77
397	Evolution of lipid profile, liver function, and pattern of plasma fatty acids according to the type of lipid emulsion administered in parenteral nutrition in the early postoperative period after digestive surgery. <b>2009</b> , 33, 501-12	19
396	Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: a population-based cohort study. <b>2009</b> , 202, 617-22	40
395	Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. <b>2009</b> , 203, 593-8	19

394	C-reactive protein predicts functional status and correlates with left ventricular ejection fraction in patients with chronic stable angina. <b>2009</b> , 205, 319-24	12
393	Neopterin levels and left ventricular dysfunction in patients with chronic stable angina pectoris. <b>2009</b> , 207, 514-8	17
392	Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. <b>2009</b> , 15, 256-66	103
391	Effect of interleukin 6 deficiency on the expression of Bcl-2 and Bax in the murine heart. <b>2009</b> , 61, 504-13	14
390	Effects of physical activity on cardiovascular and noncardiovascular outcomes in older adults. <b>2009</b> , 25, 677-702, viii-ix	57
389	What we may expect from biomarkers in heart failure. <b>2009</b> , 5, 463-70	11
388	The role of statins in chronic heart failure. <b>2009</b> , 24, 167-71	5
387	Elevated arterial stiffness evaluated by brachial-ankle pulse wave velocity is deleterious for the prognosis of patients with heart failure. <b>2009</b> , 73, 673-80	74
386	Income, education, and inflammation: differential associations in a national probability sample (The MIDUS study). <b>2010</b> , 72, 290-300	115
385	Biologic risk markers for coronary heart disease: nonlinear associations with income. <b>2010</b> , 21, 38-46	24
384	Atrial fibrillation in women. <b>2010</b> , 7, 139-146	1
383	Beneficial effects of adaptive servo ventilation in patients with chronic heart failure. <b>2010</b> , 74, 2118-24	64
382	Early detection of myocardial dysfunction and heart failure. <b>2010</b> , 7, 334-44	64
381	Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure. <b>2010</b> , 25, 392-9	12
380	Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence. <b>2010</b> , 45, 893-905	330
379	Biomarkers in heart failure: a clinical review. <b>2010</b> , 15, 251-73	19
378	Biomarkers of inflammation in heart failure. <b>2010</b> , 15, 331-41	153
377	TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. <b>2010</b> , 127, 295-314	303

376	A new regulation of IL-6 production in adult cardiomyocytes by beta-adrenergic and IL-1 beta receptors and induction of cellular hypertrophy by IL-6 trans-signalling. <b>2010</b> , 22, 1143-52	39
375	Individual and joint associations of obesity and physical activity on the risk of heart failure. <b>2010</b> , 16, 292-9	8
374	ARBITER-6 HALTS and lipid concentrations and heart failure incidence: Framingham Heart Study. <b>2010</b> , 13, 141-4	
373	Different characteristics of chronic heart failure (CHF) in elderly diabetics and non-diabetics. <b>2010</b> , 50, 101-4	2
372	Long-term outcome after thrombectomy in acute myocardial infarction. <b>2010</b> , 40, 233-41	6
371	Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. <b>2010</b> , 4, 383-413	76
370	Stress and Immune Functions*. <b>2010</b> , 531-547	
369	Population-based study of lung function and incidence of heart failure hospitalisations. <b>2010</b> , 65, 633-8	44
368	Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements. <b>2010</b> , 56, 1718-24	29
367	Multimarker approach for the prediction of heart failure incidence in the community. <i>Circulation</i> , <b>2010</b> , 122, 1700-6	16.7 94
366	Multiple cytokine biomarkers in heart failure. <b>2010</b> , 10, 147-57	16
365	Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review. <b>2010</b> , 91, 46-63	320
364	Molecular determinants of the cardiometabolic phenotype. <b>2010</b> , 10, 109-23	4
363	Iron deficiency and heart disease: ironclad evidence?. <b>2010</b> , 2010, 348-50	5
362	Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. <b>2010</b> , 31, 875-82	53
361	Inflammatory cytokines in heart failure: roles in aetiology and utility as biomarkers. <b>2010</b> , 31, 768-70	38
360	TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection. <b>2010</b> , 2, 511-20	38
359	Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. <b>2010</b> , 55, 283-93	144

358	Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. <b>2010</b> , 55, 2129-37	284
357	Determining the C-reactive protein level in patients with different clinical forms of chagas disease. <b>2010</b> , 63, 1096-9	7
356	Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. <b>2010</b> , 77, 550-6	187
355	Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. <b>2010</b> , 12, 951-7	71
354	Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure. <b>2010</b> , 16, 873-9	31
353	Effect of exercise training on chronic inflammation. <b>2010</b> , 411, 785-93	319
352	Anthracycline, Herceptin, and CV Toxicity. <b>2010</b> , 413-427	1
351	Determinaci3n de la concentraci3n plasm3tica de prote3na C reactiva en pacientes con diferentes formas cl3nicas de la enfermedad de Chagas. <b>2010</b> , 63, 1096-1099	12
350	Biomarkers of Cardiac Injury. <b>2010</b> , 119-155	1
349	Circulating soluble CTLA-4 is related to inflammatory markers in the 70 year old population. <b>2010</b> , 70, 237-43	8
348	Heart failure: pentraxin 33 marker of diastolic dysfunction and HF?. <b>2011</b> , 8, 246-8	17
347	Relationship of plasma interleukin-6 and its genetic variants with hypertension in Hong Kong Chinese. <b>2011</b> , 24, 1331-7	18
346	La insuficiencia card3aca en el siglo XXI. Epidemiolog3a y consecuencias econ3micas. <b>2011</b> , 18, 83-89	3
345	Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. <b>2011</b> , 57, 861-9	122
344	Predictors of in-hospital mortality in children after long-term ventricular assist device insertion. <b>2011</b> , 58, 1183-90	36
343	Multimarker approach for heart failure management: perspectives and limitations. <b>2011</b> , 64, 11-24	17
342	The Use of Biomarkers in the Evaluation of Heart Failure. <b>2011</b> , 545-559	1
341	On-line hemodiafiltration in the large RISCAVID study. <b>2011</b> , 175, 117-128	6



340	Inflammatory markers in population studies of aging. <b>2011</b> , 10, 319-29	539
339	White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) Study. <b>2011</b> , 21, 739-48	43
338	Serum pregnancy-associated plasma protein a in patients with heart failure. <b>2011</b> , 17, 819-26	16
337	Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. <b>2011</b> , 30, 408-13	28
336	Pentraxin 3 as a new biomarker of diastolic dysfunction. <b>2011</b> , 152, 106-7	2
335	Normal preoperative white blood cell count is predictive of outcomes for endovascular procedures. <b>2011</b> , 54, 1395-1403.e2	12
334	Myocardial Basis for Heart Failure. <b>2011</b> , 85-102	
333	The Evolution of Biocompatibility: From Microinflammation to Microvesicles. <b>2011</b> ,	
332	Epidemiology of Heart Failure. <b>2011</b> , 346-354	
331	Establishing prognosis in heart failure: a multimarker approach. <b>2011</b> , 54, 86-96	38
330	Current applications and Future Needs for Biomarkers in Pediatric Cardiomyopathy and Heart Failure: Summary From The Second International Conference On Pediatric Cardiomyopathy. <b>2011</b> , 32, 11-14	15
329	The promise of cardiovascular biomarkers in assessing children with cardiac disease and in predicting cardiovascular events in adults. <b>2011</b> , 32, 25-34	6
328	Changes in healthy elderly women's physical performance: a 3-year follow-up. <b>2011</b> , 46, 929-33	18
327	Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials. <b>2011</b> , 34, 117-23	28
326	TNF $\alpha$ in myocardial ischemia/reperfusion, remodeling and heart failure. <b>2011</b> , 16, 49-69	175
325	Measures of body composition and risk of heart failure in the elderly: the Rotterdam study. <b>2011</b> , 15, 393-7	4
324	Information encoded in a network of inflammation proteins predicts clinical outcome after myocardial infarction. <b>2011</b> , 4, 59	20
323	Biomarkers in pediatric heart failure: Their role in diagnosis and evaluating disease progression. <b>2011</b> , 31, 53-57	7

322	Deception of trans fats on Food and Drug Administration food labels: a proposed revision to the presentation of trans fats on food labels. <b>2011</b> , 25, 157-8		4
321	Mean platelet volume: a link between thrombosis and inflammation?. <b>2011</b> , 17, 47-58		789
320	Absence of SOCS3 in the cardiomyocyte increases mortality in a gp130-dependent manner accompanied by contractile dysfunction and ventricular arrhythmias. <i>Circulation</i> , <b>2011</b> , 124, 2690-701	16.7	32
319	Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response. <b>2011</b> , 3, 100ra90		40
318	Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study. <b>2011</b> , 4, 450-5		19
317	Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham Offspring Cohort. <b>2011</b> , 141, 2186-90		56
316	Neurohormonal activation in acute heart failure: results from VERITAS. <b>2011</b> , 119, 96-105		44
315	A high intake of trans fatty acids has little effect on markers of inflammation and oxidative stress in humans. <b>2011</b> , 141, 1673-8		42
314	IRF3 regulates cardiac fibrosis but not hypertrophy in mice during angiotensin II-induced hypertension. <b>2011</b> , 25, 1531-43		34
313	C-reactive Protein as a Predictor of Adverse outcome in Patients with Acute Coronary Syndrome. <b>2012</b> , 13, 7-12		20
312	Plasma calprotectin levels reflect disease severity in patients with chronic heart failure. <b>2012</b> , 19, 999-1004		9
311	Inflammation, aging, and adiposity: implications for physical therapists. <b>2012</b> , 35, 86-94		20
310	Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. <b>2012</b> , 58, 1673-81		124
309	Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. <b>2012</b> , 14, 992-9		72
308	Differential white blood cell count and incident heart failure in men and women in the EPIC-Norfolk study. <b>2012</b> , 33, 523-30		37
307	Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends?. <b>2012</b> , 5, 768-82		40
306	Emerging biomarkers in heart failure. <b>2012</b> , 58, 127-38		179
305	Inflammatory proteins and the severity of dilated Virchow-Robin Spaces in the elderly. <b>2013</b> , 33, 323-8		23

304	Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. <b>2012</b> , 157, 160-8	63
303	From risk factors to structural heart disease: the role of inflammation. <b>2012</b> , 8, 113-23	46
302	High-sensitivity C-reactive protein as an independent predictor of progressive myocardial functional deterioration: the multiethnic study of atherosclerosis. <b>2012</b> , 164, 251-8	28
301	Are patients with inflammatory bowel disease at increased risk of coronary artery disease?. <b>2012</b> , 125, 956-62	41
300	The distant organ effects of acute kidney injury. <b>2012</b> , 81, 942-948	180
299	Biomarkers. <b>2012</b> , 8, 207-24	7
298	Role of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure. <b>2012</b> , 8, 101-11	17
297	G-Protein-Coupled Receptors in the Heart. <b>2012</b> , 87-112	
296	Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence. <b>2012</b> , 116, 1139-48	129
295	Chronic treatment of mice with leukemia inhibitory factor does not cause adverse cardiac remodeling but improves heart function. <b>2012</b> , 23, 191-7	12
294	Inflammatory markers in coronary artery disease. <b>2012</b> , 38, 320-8	32
293	Evaluation of the inflammatory response to two different intensities of exercise in individuals with heart failure. <b>2012</b> , 35, 509-15	5
292	The relationship between D-dimer level and the development of atrial fibrillation in patients with systolic heart failure. <b>2012</b> , 33, 343-8	11
291	Relations of circulating resistin and adiponectin and cardiac structure and function: the Framingham Offspring Study. <b>2012</b> , 20, 1882-6	51
290	Extracorporeal ultrafiltration vs. conventional diuretic therapy in advanced decompensated heart failure. <b>2012</b> , 18, 54-63	40
289	Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. <b>2012</b> , 64, 42-52	49
288	Positioning of inflammatory biomarkers in the heart failure landscape. <b>2013</b> , 6, 485-92	53
287	Clinical correlates of change in inflammatory biomarkers: The Framingham Heart Study. <b>2013</b> , 228, 217-23	38

286	Vitamin D in heart failure. <b>2013</b> , 19, 692-711	18
285	Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases. <b>2013</b> , 24, 385-92	54
284	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. <b>2013</b> , 167, 1772-82	53
283	Response to "The prognostic implication of high-sensitivity C-reactive protein in patients with established cardiomyopathy". <b>2013</b> , 165, e19	
282	Serum $\beta$ -carotene and the risk of sudden cardiac death in men: a population-based follow-up study. <b>2013</b> , 226, 172-7	38
281	An inverse correlation between TNF alpha serum levels and heart rate variability in patients with heart failure. <b>2013</b> , 62, 37-43	25
280	Serum $\beta$ -carotene concentrations and the risk of congestive heart failure in men: a population-based study. <b>2013</b> , 168, 1841-6	41
279	Heart failure. <b>2013</b> , 1, 1-20	481
278	Proinflammatory cytokines, aging, and age-related diseases. <b>2013</b> , 14, 877-82	572
277	Pathophysiology of Heart Failure. <b>2013</b> , 327-345	2
276	Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up. <b>2013</b> , 138, 467-73	14
275	Beyond gout: uric acid and cardiovascular diseases. <b>2013</b> , 29 Suppl 3, 33-9	31
274	De Gruyter. <b>2013</b> , 21,	2
273	Risk factors affecting cardiac left-ventricular hypertrophy and systolic and diastolic function in the chronic phase of allogeneic hematopoietic cell transplantation. <b>2013</b> , 48, 581-6	2
272	The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction. <b>2013</b> , 41, 2080-7	27
271	Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure. <b>2013</b> , 124, 115-22	30
270	Endothelin receptor blocker bosentan inhibits hypertensive cardiac fibrosis in pressure overload-induced cardiac hypertrophy in rats. <b>2013</b> , 2, 85-97	35
269	Elevated levels of interleukin 6 and C-reactive protein associated with cognitive impairment in heart failure. <b>2013</b> , 19, 92-8	37

268	Inflammation, blood pressure and cardiovascular disease: heading east. <b>2013</b> , 27, 71	1
267	Inflammatory markers in heart failure: hype or hope?. <b>2013</b> , 14, 342-50	4
266	High-glucose-based peritoneal dialysis solution induces the upregulation of VEGF expression in human peritoneal mesothelial cells: The role of pleiotrophin. <b>2013</b> , 32, 1150-8	11
265	[Clinical usefulness of biomarkers in cardiac failure]. <b>2013</b> , 141, 1560-9	1
264	Cardiovascular risk factor investigation: a pediatric issue. <b>2013</b> , 6, 57-66	39
263	The association between COPD and heart failure risk: a review. <b>2013</b> , 8, 305-12	102
262	Obesity and heart failure. <b>2013</b> , 13, 51-7	23
261	Left ventricular mass in dialysis patients, determinants and relation with outcome. Results from the CONvective TRANsport STudy (CONTRAST). <b>2014</b> , 9, e84587	19
260	Serum iron concentration, but not hemoglobin, correlates with TIMI risk score and 6-month left ventricular performance after primary angioplasty for acute myocardial infarction. <b>2014</b> , 9, e104495	19
259	The role of oxidative stress and inflammation in cardiovascular aging. <b>2014</b> , 2014, 615312	133
258	Cardiorespiratory fitness and risk of heart failure: a population-based follow-up study. <b>2014</b> , 16, 180-8	72
257	Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes. <b>2014</b> , 15, 759-74	9
256	Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study. <b>2014</b> , 7, 5-11	30
255	A meta-analysis of proinflammatory cytokines in chronic heart failure. <b>2014</b> , 6, 130-6	21
254	Management of cardiovascular risk factors in adults with congenital heart disease. <b>2014</b> , 3, e001076	48
253	Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers. <b>2014</b> , 16, 373-89	38
252	Plasma vitamin C and risk of hospitalisation with diagnosis of atrial fibrillation in men and women in EPIC-Norfolk prospective study. <b>2014</b> , 177, 830-5	12
251	Whole blood gene expression and interleukin-6 levels. <b>2014</b> , 104, 490-5	19

250	Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and women. <b>2014</b> , 66, 1233-40	29
249	Protective actions of melatonin and growth hormone on the aged cardiovascular system. <b>2014</b> , 18, 79-88	17
248	In patients with stable heart failure, soluble TNF-receptor 2 is associated with increased risk for depressive symptoms. <b>2014</b> , 16, 295-302	11
247	Effects of atrial natriuretic peptide on inter-organ crosstalk among the kidney, lung, and heart in a rat model of renal ischemia-reperfusion injury. <b>2014</b> , 2, 28	28
246	C-reactive protein: clinical and epidemiological perspectives. <b>2014</b> , 2014, 605810	61
245	C-reactive protein is elevated in heart failure patients with central sleep apnea and Cheyne-Stokes respiration. <b>2014</b> , 87, 113-20	17
244	Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction. <b>2014</b> , 3,	18
243	Curcuma oil reduces endothelial cell-mediated inflammation in postmyocardial ischemia/reperfusion in rats. <b>2014</b> , 64, 228-36	16
242	Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry). <b>2014</b> , 113, 511-7	29
241	Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: a population-based study (CoLaus Study). <b>2014</b> , 66, 95-100	17
240	NF- $\kappa$ B signaling and chronic inflammatory diseases: exploring the potential of natural products to drive new therapeutic opportunities. <b>2014</b> , 19, 373-8	70
239	Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease. <b>2014</b> , 167, 707-14	17
238	Healthy lifestyle and decreasing risk of heart failure in women: the Women's Health Initiative observational study. <b>2014</b> , 64, 1777-85	59
237	Statins as adjunct therapy in COPD: how do we cope after STATCOPE?. <b>2014</b> , 69, 891-4	21
236	Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence. <b>2014</b> , 11, 337-46	22
235	Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. <b>2014</b> , 13, 126	57
234	Multifunctional MR monitoring of the healing process after myocardial infarction. <b>2014</b> , 109, 430	25
233	Cardiac biomarkers in heart failure. <b>2014</b> , 47, 327-37	39

232	The influence of pericardial fat upon left ventricular function in obese females: evidence of a site-specific effect. <b>2014</b> , 16, 37	21
231	Chronic obstructive pulmonary disease: pathophysiological impact on heart failure in real clinical situation. <b>2014</b> , 64, 250-2	3
230	Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure. <b>2014</b> , 10, 339-52	41
229	Elevated levels of pro-inflammatory oxylipins in older subjects are normalized by flaxseed consumption. <b>2014</b> , 59, 51-7	49
228	[Acute kidney injury: progress in diagnosis and treatments. Topics: IV. Pathophysiology and treatments; 8. Distant organ dysfunction associated with AKI]. <b>2014</b> , 103, 1123-9	
227	[Cardiomyopathy: progress in diagnosis and treatments. Topics: III. Diagnosis leading to selection of therapy: 2. Biomarker]. <b>2014</b> , 103, 345-52	
226	Effect of Cardiac Resynchronization Therapy on Inflammation in Congestive Heart Failure: A Review. <b>2015</b> , 82, 191-8	3
225	Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials. <b>2015</b> , 33, 338-46	35
224	Technological Aspects of Measuring Inflammatory Markers. <b>2015</b> , 117-130	
223	Inflammatory Biomarkers in Refractory Congestive Heart Failure Patients Treated with Peritoneal Dialysis. <b>2015</b> , 2015, 590851	6
222	Role of tumor necrosis factor alpha in the pathogenesis of atrial fibrillation: A novel potential therapeutic target?. <b>2015</b> , 47, 316-24	23
221	The lymphocyte-to-monocyte ratio: an added value for death prediction in heart failure. <b>2015</b> , 25, 1033-40	23
220	Inflammatory Biomarkers in Post-infarction Heart Failure and Cardiac Remodeling. <b>2015</b> , 105-116	
219	Predicting therapeutic response in patients with heart failure: the story of C-reactive protein. <b>2015</b> , 13, 153-61	9
218	Interleukin-6 as a first-rated serum inflammatory marker to predict mortality and hospitalization in the oldest old: A regression and CART approach in the BELFRAIL study. <b>2015</b> , 69, 53-61	23
217	Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy. <b>2015</b> , 43, 31-44	6
216	Intermediate and long-term risk of new-onset heart failure after hospitalization for pneumonia in elderly adults. <b>2015</b> , 170, 306-12	42
215	Matrix Metalloproteinase 9 (MMP-9). <b>2015</b> , 237-259	1

214	The paradox of bardoxolone methyl: a call for every witness on the stand?. <b>2015</b> , 17, 9-14	16
213	Heart Failure in Women--Insights from the Framingham Heart Study. <b>2015</b> , 29, 377-90	39
212	Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease. <b>2015</b> , 16, 1175-84	5
211	Pro-inflammatory cytokines correlate with classical risk factors for atherosclerosis in the admixed Brazilian older women. <b>2015</b> , 60, 142-6	8
210	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. <b>2015</b> , 443, 29-38	58
209	Methanolic Extract of Ceplukan Leaf ( <i>Physalis minima</i> L.) Attenuates Ventricular Fibrosis through Inhibition of TNF- $\alpha$ in Ovariectomized Rats. <b>2016</b> , 2016, 2428052	1
208	Role of TFEB Mediated Autophagy, Oxidative Stress, Inflammation, and Cell Death in Endotoxin Induced Myocardial Toxicity of Young and Aged Mice. <b>2016</b> , 2016, 5380319	33
207	Fatigue in Older Adults Postmyocardial Infarction. <b>2016</b> , 4, 55	5
206	Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. <b>2016</b> , 67, 544-51	73
205	Atrial Fibrillation and Cardiovascular Outcomes in the Elderly. <b>2016</b> , 39, 907-13	18
204	Frailty and sarcopenia as the basis for the phenotypic manifestation of chronic diseases in older adults. <b>2016</b> , 50, 1-32	74
203	ECG low QRS voltage and wide QRS complex predictive of centenarian 360-day mortality. <b>2016</b> , 38, 44	4
202	Vascular risk assessment in older adults without a history of cardiovascular disease. <b>2016</b> , 79, 37-45	6
201	Heart Failure and Inflammatory Arthritis: the Relationship of Systemic Inflammation. <b>2016</b> , 10, 1	
200	How to Best Identify Elderly Individuals Who May Develop Heart Failure. <b>2016</b> , 10, 1	
199	Relation of Magnesium Intake With Cardiac Function and Heart Failure Hospitalizations in Black Adults: The Jackson Heart Study. <b>2016</b> , 9, e002698	20
198	Orosomuroid is an independent predictor of prognosis in chronic heart failure. <b>2016</b> , 128, 870-874	4
197	Anxiety Disorders and Cardiovascular Disease. <b>2016</b> , 18, 101	111



196	Interleukin-6 and C-reactive protein, successful aging, and mortality: the PolSenior study. <b>2016</b> , 13, 21		170
195	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , <b>2016</b> , 134, e535-e578	16.7	164
194	Effects of Long-Term Exercise on Age-Related Hearing Loss in Mice. <b>2016</b> , 36, 11308-11319		30
193	Chronic Heart Failure and Inflammation: What Do We Really Know?. <b>2016</b> , 119, 159-76		286
192	Non-carbonyl Curcuma longa [NCCL] protects the heart from myocardial ischemia/reperfusion injury by reducing endothelial microparticle mediated inflammation in rats. <b>2016</b> , 6, 54938-54948		3
191	Intercellular Adhesion Molecule 1 Regulates Left Ventricular Leukocyte Infiltration, Cardiac Remodeling, and Function in Pressure Overload-Induced Heart Failure. <b>2016</b> , 5, e003126		67
190	Evaluation and comparison of biomarkers in heart failure. <b>2016</b> , 68 Suppl 1, S22-8		4
189	Body Mass Index, Abdominal Fatness, and Heart Failure Incidence and Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies. <i>Circulation</i> , <b>2016</b> , 133, 639-49	16.7	197
188	Effect of magnesium sulfate and thyroxine on inflammatory markers in a rat model of hypothyroidism. <b>2016</b> , 94, 426-32		5
187	Cardiovascular risk factors and inflammatory activity among centenarians with and without dementia. <b>2017</b> , 29, 411-417		10
186	Cardiometabolic biomarkers are predictors of readmission and death in patients hospitalized for acute dyspnea. <b>2017</b> , 35, 610-614		3
185	Fragility Fractures Are Associated with an Increased Risk for Cardiovascular Events in Women and Men with Rheumatoid Arthritis: A Population-based Study. <b>2017</b> , 44, 558-564		9
184	Skeletal muscle inflammation and atrophy in heart failure. <b>2017</b> , 22, 179-189		39
183	GRK2 Mediates Arginine Vasopressin-Induced Interleukin-6 Production via Nuclear Factor- $\kappa$ B Signaling Neonatal Rat Cardiac Fibroblast. <b>2017</b> , 92, 278-284		15
182	Endogenous bone morphogenetic protein 2 plays a role in vascular smooth muscle cell calcification induced by interleukin 6 in vitro. <b>2017</b> , 30, 227-237		33
181	Role of Inflammation in Heart Failure. <b>2017</b> , 19, 27		129
180	Epidemiology of Cardio-Oncology. <b>2017</b> , 1-14		1
179	Aerobic fitness, muscular strength and obesity in relation to risk of heart failure. <b>2017</b> , 103, 1780-1787		24

178	Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1 $\beta$ and IL-6-Related Impairment of Bone Marrow Function. <b>2017</b> , 120, 1947-1957	27
177	Role of Adipose Tissue Endothelial ADAM17 in Age-Related Coronary Microvascular Dysfunction. <b>2017</b> , 37, 1180-1193	35
176	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. <b>2017</b> , 5, 507-517	49
175	Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study. <b>2017</b> , 6,	47
174	The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?. <b>2017</b> , 178, 67-82	2
173	Cardiorespiratory fitness and incident heart failure: The Henry Ford Exercise Testing (FIT) Project. <b>2017</b> , 185, 35-42	32
172	Does statins promote vascular calcification in chronic kidney disease?. <b>2017</b> , 47, 137-148	48
171	Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. <b>2017</b> , 63, 211-222	25
170	The effect of Ezetimibe and Simvastatin Combination Therapy on percutaneous coronary intervention patients. <b>2017</b> , 242, 1-3	8
169	Skeletal muscle alterations in HFrEF vs. HFpEF. <b>2017</b> , 14, 489-497	19
168	High-sensitivity C reactive protein as a predictor of in-hospital mortality in patients with cardiovascular disease at an emergency department: a retrospective cohort study. <b>2017</b> , 7, e015112	15
167	A Role of Remote Organs Effect in Acute Kidney Injury Outcome. <b>2017</b> , 137, 273-276	19
166	The role of procalcitonin in acute heart failure patients. <b>2017</b> , 4, 203-208	18
165	Associations of tumor necrosis factor alpha receptor type 1 with kidney function decline, cardiovascular events, and mortality risk in persons with coronary artery disease: Data from the Heart and Soul Study. <b>2017</b> , 263, 68-73	6
164	Associations of TNFR1 with kidney function outcomes by age, gender, and baseline kidney function status: Data from the Heart and Soul Study. <b>2017</b> , 14, 366-370	
163	MiRNA Deregulation in Cardiac Aging and Associated Disorders. <b>2017</b> , 334, 207-263	18
162	An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. <b>2017</b> , 113, 378-388	109
161	Proinflammatory Cytokines Mediate GPCR Dysfunction. <b>2017</b> , 70, 61-73	8

160	Inflammation - Cause or Consequence of Heart Failure or Both?. <b>2017</b> , 14, 251-265	211
159	Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. <b>2017</b> , 226, 53-59	41
158	Evaluation of human nonmercaptalbumin as a marker for oxidative stress and its association with various parameters in blood. <b>2017</b> , 61, 79-84	15
157	Identification of the difference in the pathogenesis in heart failure arising from different etiologies using a microarray dataset. <b>2017</b> , 72, 600-608	7
156	The rs2228145 polymorphism in the interleukin-6 receptor and its association with long-term prognosis after myocardial infarction in a pilot study. <b>2017</b> , 13, 93-99	3
155	Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: A report from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). <b>2017</b> , 12, e0177684	32
154	Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. <b>2017</b> , 16, 130	36
153	IRON DEFICIENCY AND ANEMIA IN PATIENTS WITH CHRONIC HEART FAILURE. <b>2017</b> , 13, 651-660	9
152	Determinants of Aortic Size and Stiffness and the Impact on Exercise Physiology in Patients After the Fontan Operation. <b>2017</b> , 58, 73-80	7
151	Neutrophil counts and their potential prognostic value in cardiovascular diseases. <b>2017</b> , 2, 30-30	3
150	Involvement of IL-1 $\alpha$ and IL-6 in antiarrhythmic properties of atorvastatin in ouabain-induced arrhythmia in rats. <b>2018</b> , 40, 256-261	2
149	Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction. <b>2018</b> , 5, 211-221	18
148	Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. <b>2018</b> , 257, 188-192	23
147	Central Sleep Apnea with Cheyne-Stokes Breathing in Heart Failure - From Research to Clinical Practice and Beyond. <b>2018</b> , 1067, 327-351	11
146	Cardiovascular biomarkers in clinical studies of type 2 diabetes. <b>2018</b> , 20, 1350-1360	13
145	Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. <b>2018</b> , 3, 215-224	115
144	Cardiac and inflammatory biomarkers in perinatally HIV-infected and HIV-exposed uninfected children. <b>2018</b> , 32, 1267-1277	9
143	Troponin and BNP are markers for subsequent non-ischaemic congestive heart failure: the Caerphilly Prospective Study (CaPS). <b>2018</b> , 5, e000692	5

142	Genetic ablation of TRPV1 exacerbates pressure overload-induced cardiac hypertrophy. <b>2018</b> , 99, 261-270	17
141	Attenuated strength gains during prolonged resistance exercise training in older adults with high inflammatory status. <b>2018</b> , 106, 154-158	12
140	Interleukin-1 blockade in cardiovascular diseases: a clinical update. <b>2018</b> , 39, 2063-2069	85
139	A Conceptual Framework Encompassing the Psychoneuroimmunoendocrinological Influences of Listening to Music in Patients With Heart Failure. <b>2018</b> , 32, 81-89	6
138	Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China. <b>2018</b> , 69, 49-58	12
137	Impact of caregiving for older people and pro-inflammatory biomarkers among caregivers: a systematic review. <b>2018</b> , 30, 119-132	26
136	Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases. <b>2018</b> , 55, 254-270	1
135	Arterial inflammation measured by F-FDG-PET-CT to predict coronary events in older subjects. <b>2018</b> , 268, 49-54	15
134	The revised GOLD 2017 COPD categorization in relation to comorbidities. <b>2018</b> , 134, 79-85	34
133	Exploration of Predictive Biomarkers for Sudden Unexplained Cardiac Death in Nonelderly People: A Case-Control Study With Biochemical Parameters Related to Heart Failure. <b>2018</b> , 39, 41-45	3
132	Novel applications for serum procalcitonin testing in clinical practice. <b>2018</b> , 18, 27-34	25
131	Hartfalen en COPD. <b>2018</b> , 34, 448-455	
130	C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction. <b>2018</b> , 5, 178	10
129	Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction. <b>2018</b> , 7, e009098	29
128	Working Toward an Improved Understanding of Chronic Cardiorenal Syndrome Type 4. <b>2018</b> , 25, 454-467	2
127	Anthracycline, Trastuzumab, and Cardiovascular Toxicity. <b>2018</b> , 432-446	
126	Recent advances in designing nanomaterial based biointerfaces for electrochemical biosensing cardiovascular biomarkers. <b>2018</b> , 161, 344-376	25
125	Inflammatory Mediators in Heart Failure. <b>2018</b> , 33-50	


124	Natriuretic and Inflammatory Biomarkers as Risk Predictors of Heart Failure in Middle-Aged Men From the General Population: A 21-Year Follow-Up. <b>2018</b> , 24, 594-600	3
123	Declining Lung Function and Cardiovascular Risk: The ARIC Study. <b>2018</b> , 72, 1109-1122	30
122	Predictive value of long-term changes of growth differentiation factor-15 over a 27-year-period for heart failure and death due to coronary heart disease. <b>2018</b> , 13, e0197497	15
121	Organ crosstalk: the potent roles of inflammation and fibrotic changes in the course of organ interactions. <b>2019</b> , 68, 825-839	20
120	Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte. <b>2019</b> , 20,	40
119	Attenuation of diabetic cardiomyopathy by relying on kirenol to suppress inflammation in a diabetic rat model. <b>2019</b> , 23, 7651-7663	25
118	Cytokines in heart failure. <b>2019</b> , 93, 63-113	8
117	Sarcopenia en pacientes coronarios hospitalizados. <b>2019</b> , 46, 11-17	2
116	Biomarkers in heart failure: the past, current and future. <b>2019</b> , 24, 867-903	48
115	Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. <b>2019</b> , 34, 1961-1968	23
114	Heart Failure, the Inflammasome, and Interleukin-1 $\beta$ Prognostic and Therapeutic?. <b>2019</b> , 73, 1026-1028	4
113	Neopterin is Associated with Disease Severity and Outcome in Patients with Non-Ischaemic Heart Failure. <b>2019</b> , 8,	7
112	Predictors for congestive heart failure hospitalization or death following acute pulmonary embolism: A population-linkage study. <b>2019</b> , 278, 162-166	3
111	Pre- and post-diagnosis body mass index and heart failure mortality: a dose-response meta-analysis of observational studies reveals greater risk of being underweight than being overweight. <b>2018</b> , 20, 252-261	9
110	From pediatrics to geriatrics: Mechanisms of heart failure across the life-course. <b>2019</b> , 126, 70-76	4
109	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. <i>Circulation</i> , <b>2019</b> , 139, 1289-1299	16.7 223
108	Novel biomarkers of cardiovascular disease: Applications in clinical practice. <b>2019</b> , 56, 33-60	37
107	Elevated Sera sST2 Is Associated With Heart Failure in Men $\geq$ 50 Years Old With Myocarditis. <b>2019</b> , 8, e008968	29

106	Interleukin 6 Knockout Inhibits Aging-Related Accumulation of p53 in the Mouse Myocardium. <b>2019</b> , 74, 176-182	4
105	Release of mitochondrial DNA is associated with mortality in severe acute heart failure. <b>2020</b> , 9, 419-428	5
104	Arrestin 2 mediates arginine vasopressin-induced IL-6 induction via the ERK-NF- $\kappa$ B signal pathway in murine hearts. <b>2020</b> , 41, 198-207	8
103	Reappraisal of Inflammatory Biomarkers in Heart Failure. <b>2020</b> , 17, 9-19	9
102	Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype. <b>2020</b> , 27, 73-80	7
101	Does tooth brushing protect from atrial fibrillation and heart failure?. <b>2020</b> , 27, 1832-1834	
100	Inflammation, non-endothelial dependent coronary microvascular function and diastolic function-Are they linked?. <b>2020</b> , 15, e0236035	8
99	Effect of Renal Denervation on Cardiac Function and Inflammatory Factors in Heart Failure After Myocardial Infarction. <b>2020</b> , 76, 602-609	1
98	The inflammatory markers sST2, HSP27 and hsCRP as a prognostic biomarker panel in chronic heart failure patients. <b>2020</b> , 510, 507-514	5
97	Differentially expressed lnc-NOS2P3-miR-939-5p axis in chronic heart failure inhibits myocardial and endothelial cells apoptosis via iNOS/TNF $\alpha$ pathway. <b>2020</b> , 24, 11381-11396	6
96	Epidemiology of heart failure. <b>2020</b> , 22, 1342-1356	234
95	Circulating protein biomarkers predict incident hypertensive heart failure independently of N-terminal pro-B-type natriuretic peptide levels. <b>2020</b> , 7, 1891-1899	3
94	The role of diabetes in cardiomyopathies of different etiologies-Characteristics and 1-year follow-up results of the EVITA-HF registry. <b>2020</b> , 15, e0234260	1
93	Central sleep apnea and atrial fibrillation: A review on pathophysiological mechanisms and therapeutic implications. <b>2020</b> , 30, 100527	8
92	Association of soluble interleukin-2 receptor 1 and tumour necrosis factor receptor 1 with heart failure: The Multi-Ethnic Study of Atherosclerosis. <b>2020</b> , 7, 639-644	4
91	Distinctive patterns of inflammation across the heart failure syndrome. <b>2021</b> , 26, 1333-1344	19
90	Soluble CD14 and Risk of Heart Failure and Its Subtypes in Older Adults. <b>2020</b> , 26, 410-419	3
89	The inflammation-based modified Glasgow prognostic score is associated with survival in stable heart failure patients. <b>2020</b> , 7, 654-662	11

88	Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. <b>2020</b> , 17, 585-607	139
87	Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. <b>2020</b> , 126, 1260-1280	165
86	Metabolic Inflammation in Obesity-At the Crossroads between Fatty Acid and Cholesterol Metabolism. <b>2021</b> , 65, e1900482	4
85	Myocardial involvement in eosinophilic granulomatosis with polyangiitis evaluated with cardiopulmonary magnetic resonance. <b>2021</b> , 37, 1371-1381	5
84	Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study. <b>2021</b> , 77, 231-238	2
83	Derivation of an electronic frailty index for short-term mortality in heart failure: a machine learning approach.	
82	The value of C-reactive protein-to-albumin ratio in predicting long-term mortality among HFrEF patients with implantable cardiac defibrillators. <b>2021</b> , 51, e13550	1
81	Tanshinone IIA combined with CsA inhibit myocardial cell apoptosis induced by renal ischemia-reperfusion injury in obese rats. <b>2021</b> , 21, 100	2
80	Effect of chronic JUUL aerosol inhalation on inflammatory states of the brain, lung, heart and colon in mice.	
79	Biomarkers for the diagnosis and management of heart failure. <b>2021</b> , 1	11
78	Inflammatory markers and incident heart failure in older men: the role of NT-proBNP. <b>2021</b> , 15, 413-425	2
77	Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. <b>2021</b> , 128, 1728-1746	46
76	Diagnostic Thresholds for Pre-Diabetes Mellitus and Diabetes Mellitus and Subclinical Cardiac Disease in the General Population:. <b>2021</b> , 10, e020447	4
75	Derivation of an electronic frailty index for predicting short-term mortality in heart failure: a machine learning approach. <b>2021</b> , 8, 2837-2845	5
74	Association of immune cell subsets with cardiac mechanics in the Multi-Ethnic Study of Atherosclerosis. <b>2021</b> , 6,	0
73	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. <b>2021</b> , 27, 1382-1392	0
72	Resistin deletion protects against heart failure injury by targeting DNA damage response. <b>2021</b> ,	2
71	Inflammation-based assessment for the risk stratification of mortality in patients with heart failure. <b>2021</b> , 11, 14989	1

70	Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - Implications for Chronic Inflammatory Mechanisms. <b>2021</b> ,	0
69	Independent Association of Fatty Liver Index With Left Ventricular Diastolic Dysfunction in Subjects Without Medication. <b>2021</b> , 158, 139-146	0
68	Relationship Between the Eosinophil/Monocyte Ratio and Prognosis in Decompensated Heart Failure: A Retrospective Study. <b>2021</b> , 14, 4687-4696	1
67	The relationship between systemic inflammation and increased left ventricular mass is partly mediated by noncalcified coronary artery disease burden in psoriasis. <b>2021</b> , 7, 100211	2
66	Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2). <b>2017</b> , 40, 626-632	42
65	Clinical use of C-reactive protein for cardiovascular disease. <b>2004</b> , 97, 985-8	9
64	Role of interleukins in heart failure with reduced ejection fraction. <b>2019</b> , 22, 287-299	15
63	CARDIORENAL SYNDROME IN PATIENTS WITH CHRONIC HEART FAILURE AS A STAGE OF THE CARDIORENAL CONTINUUM (PART I): DEFINITION, CLASSIFICATION, PATHOGENESIS, DIAGNOSIS, EPIDEMIOLOGY. <b>2019</b> , 9, 5-22	17
62	Chronic Heart Failure in Rheumatoid Arthritis Patients (Part I): Prevalence, Etiology and Pathogenesis. <b>2018</b> , 14, 703-710	5
61	Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). <b>2020</b> , 18, 488-506	5
60	The Impact of Spironolactone on Markers of Myocardial Oxidative Status, Inflammation and Remodeling in Hyperthyroid Rats. <b>2020</b> , 13, 206-215	5
59	Measurement of serum soluble ST2 in patients with heart failure and its diagnostic value. <b>2012</b> , 32, 175-178	2
58	Relation of anti- to pro-inflammatory cytokine ratios with acute myocardial infarction. <b>2010</b> , 25, 44-50	40
57	Association of Hand Grip Strength and Cardiometabolic Markers in Korean Adult Population: The Korea National Health and Nutrition Examination Survey 2015-2016. <b>2020</b> , 41, 291-298	5
56	Molecular Signature of the Immune Response to Yoga Therapy in Stress-related Chronic Disease Conditions: An Insight. <b>2020</b> , 13, 9-17	16
55	Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. <b>2021</b> , 12, 746494	8
54	The Predictive role of Neutrophil-to-Lymphocyte Ratio (NLR) and Mean Platelet Volume-to-Lymphocyte Ratio (MPVLR) for Cardiovascular Events in Adult Patients with Acute Heart Failure. <b>2021</b> , 2021, 6889733	1
53	Molecular and Cellular Events in Myocardial Hypertrophy and Failure. <b>2005</b> , 61-81	



52	Biomarkers of Inflammation as Surrogate Markers in Detection of Vulnerable Plaques and Vulnerable Patients. <b>2007</b> , 641-651	1
51	 <b>2010</b> , 120-127	
50	Heart Failure Prevention. <b>2011</b> , 141-160	
49	Pathophysiological Aspects of Lipoprotein-Associated Phospholipase A2: A Brief Overview. <b>2014</b> , 115-133	
48	The Fontan Operation. <b>2017</b> , 313-323	
47	Diagnostic, clinical and prognostic aspects determine the concentration of C-reactive protein in chronic heart failure.. <b>2018</b> , 96, 197-207	1
46	Anxiety, Anger, Personality, and Heart Disease. <b>2020</b> , 1-18	
45	The Association Between Pneumonia and Heart failure. <b>2020</b> , 27, 125-130	0
44	Relevance of Neutrophil Nephilysin in Heart Failure. <b>2021</b> , 10,	1
43	Cardiac Troponin Elevation After Long-Distance Cycling is Associated with Oxidative Stress and Exercise Intensity: An Observational Study. <b>2020</b> , 11,	
42	Anxiety, Anger, Personality, and Heart Disease. <b>2020</b> , 243-260	
41	Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study.	
40	Pathophysiology of Heart Failure. <b>2005</b> , 347-369	
39	Induction of early biomarkers in a thrombus-induced sheep model of ischemic heart failure. <b>2013</b> , 40, 511-20	5
38	Assessing inflammation in Chinese subjects with subtypes of heart failure: an observational study of the Chinese PLA Hospital Heart Failure Registry. <b>2019</b> , 16, 313-319	2
37	Fibroblast Growth Factor-23 and Subclinical Markers of Cardiac Dysfunction: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. <b>2021</b> , 245, 10-10	1
36	Influence of Cytokines on Inflammatory Eye Diseases: A Citation Network Study.. <b>2022</b> , 11,	0
35	Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease.. <b>2021</b> , 12, 768560	6

34	Fibronectin type III domain-containing 5 improves aging-related cardiac dysfunction in mice.. <b>2022</b> , e13556	6
33	-HH Gene Variants Encoding the Fc Gamma Receptor for the C-Reactive Protein Are Associated with Enhanced Monocyte CD32 Expression and Cardiovascular EventsNRecurrence after Primary Acute Coronary Syndrome.. <b>2022</b> , 10,	1
32	HDL Composition, Heart Failure, and Its Comorbidities.. <b>2022</b> , 9, 846990	1
31	Low-Level Elevations of Procalcitonin Are Associated with Increased Mortality in Acute Heart Failure Patients, Independent of Concomitant Infection.. <b>2021</b> , 11,	
30	Recent Advances in Anxiety Disorders and Cardiovascular Diseases. <b>2022</b> , 12, 2638-2644	
29	Effects of mango and mint pod-based e-cigarette aerosol inhalation on inflammatory states of the brain, lung, heart, and colon in mice.. <b>2022</b> , 11,	2
28	Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.. <b>2021</b> , 18, 908-951	2
27	Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future. <b>2022</b> , 23, 5680	3
26	Multi-system trajectories and the incidence of heart failure in the Framingham Offspring Study. <b>2022</b> , 17, e0268576	
25	Biomarker sensing using luminescent metal nanoclusters. <b>2022</b> , 435-464	
24	Current landscape of preclinical models of diabetic cardiomyopathy. <b>2022</b> ,	0
23	The hormetic and hermetic role of IL-6. <b>2022</b> , 101697	1
22	Candidate Plasma Biomarkers to Detect Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study.	
21	A novel identified circular RNA, circSnap47, promotes heart failure progression via regulation of miR-223-3p/MAPK axis.	0
20	Periodontal Status, C-Reactive Protein, NT-proBNP, and Incident Heart Failure. <b>2022</b> ,	0
19	Associations of empirical dietary inflammatory index with heart failure in adults from the United States.	1
18	Sex-dependent mechanisms of cell death modalities in cardiovascular disease. <b>2022</b> ,	1
17	Kardiyak Resenkronizasyon Tedavisine Yanlılgımesinde Sistemik Bađılgı-flamatuvar Bdeksinin Rolü <b>2022</b> , 5, 145-154	0

- 16 Inflammation and heart failure: a two-sample Mendelian randomization study. Publish Ahead of Print, ○
- 15 Association of immune cell subsets with incident heart failure in two population-based cohorts. ○
- 14 Advances in congestive heart failure biomarkers. **2022**, ○
- 13 C-reactive protein and statins in heart failure with reduced and preserved ejection fraction. 9, ○
- 12 Inflammation and Heart Failure: Searching for the Enemy Reaching the Entelechy. **2023**, 10, 19 ○
- 11 Eicosanoid and Eicosanoid-Related Inflammatory Mediators and Exercise Intolerance in Heart Failure with Preserved Ejection Fraction. ○
- 10 Potential Biological Mediators of Myocardial and Vascular Complications of Air Pollution A State-of-the-Art Review. **2022**, ○
- 9 Prognostic Impact of Modified Glasgow Prognostic Score in Patients with Heart Failure with Mildly Reduced Ejection Fraction. **2022**, 25, 6-13 ○
- 8 Diagnostic and prognostic biomarkers reflective of cardiac remodelling in diabetes mellitus: A scoping review. **2023**, 40, ○
- 7 Inflammation, dysregulated iron metabolism, and cardiovascular disease. 4, ○
- 6 Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence. **2023**, 12, 1302 ○
- 5 The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. **2023**, 2, 122-164 ○
- 4 Comparison of Platelet Parameters and Electrocardiogram Data in Patients with Generalized Anxiety Disorder with Healthy Control Group. ○
- 3 Effect of C-reactive protein on the risk of Heart failure: a mendelian randomization study. **2023**, 23, ○
- 2 ~~2016~~ **2016**, 23-27 ○
- 1 Causal effects of circulating vitamin levels on the risk of heart failure: a Mendelian randomization study. **2023**, 20, 195-204 ○